Drug intelligence / Profile preview

PLGAI-004

Development stage: Unknown
Lead developer: Peptilogics
Modality: Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules

Overview

PLGAI-004 is a synthetic peptide-based therapeutic under development by Peptilogics for the treatment of cancer (neoplasms). It is classified as an antineoplastic agent and represents a new molecular entity. The drug is being developed using Peptilogics' AI-driven platform, Nautilus. As of the latest updates in early 2025, its mechanism of action remains undefined or undisclosed. The compound has not received orphan drug status and is currently in the discovery or early research phase with no clinical trial data reported[1][2][7].

Beyond the preview

Go deeper on PLGAI-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLGAI-004.

Explore the full profile